Disclosed are 1,3 oxazines as BACE1 and BACE2 inhibitors of formula (I), wherein the substituents are as described in the specification. The active compounds of the present disclosure are useful in the therapeutic and/or prophylactic treatment of Alzheimer&rsquo；s disease and type 2 diabetes. In one embodiment the compound is 5-Chloro-pyridine-2-carboxylic acid [3-((4R,5R)-2-amino-5-fluoro-4-methyl-5, 6-dihydro-4H[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide. In another embodiment the compound is 3,5-Dichloro-pyridine-2-carboxylic acid [3-((4R, 5R)-2-amino-5-fluoro-4-methyl-5, 6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide. In yet another embodiment the compound is 5-Cyano-pyridine-2-carboxylic acid [3-((4 R, 5R)-2-amino-5-fluoro-4-methy 1-5, 6-dihydro-4H[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide.
